News
Archive
Ventyx Biosciences reports clinical data for its NLRP3 inhibitor portfolio and provides pipeline updates at virtual investor event
NorthSea Therapeutics initiates Phase 2A trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)
Resolve Therapeutics announces publication of Lupus clinical trial results
biomodal delivers the 6-base genome with a powerful new multiomic solution, duet evoC
InvestEU in Belgium: EIB venture debt for bone therapy innovator Novadip
Repeated Signal Solutions, Inc. and Avari Wireless Inc. announce Enhanced ERCES Monitoring
Back To News
October 17, 2017
Biovex
Acquired by Amgen. Focused on the development of an oncolytic vaccine for melanoma and head and neck cancer.